|
Phase IIIb, Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness & Safety of the use of Carbaglu® in Patients with Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA)
|
Ongoing
|
Carglumic acid
|
3
|
IIT-OE-2013-001
|
King Abdulaziz Medical City NG (Riyadh)_ King Fahad Medical City (Riyadh)
|
|
A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
|
Ongoing
|
Sorafenib
|
3
|
BAY43-9006/14295
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A Randomized, Multi-Center Study to Evaluate Cardiovascular Outcomes With ITCA 650 in Patients Treated With Standard of Care for Type 2 Diabetes
|
Completed
|
ITCA 650
|
3
|
ITCA 650-CLP-107
|
King Abdulaziz Medical City NG (Jeddah)_ King Abdulaziz Hospital NG (Al Ahsa)
|
|
Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy and Safety of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Subjects With Congenital Fibrinogen Deficiency
|
Ongoing
|
Octafibrin
|
3
|
Forma 02
|
King Khalid University Hospital (Riyadh)
|
|
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis
|
Ongoing
|
Purified Poloxamer 188
|
3
|
MST-188-01
|
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh), Maternity and Children's Hospital (Al Ahsa)_ King Fahad Medical City (Riyadh)_ King Abdulaziz University Hospital (Jeddah)
|
|
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)
|
Ongoing
|
ABT-450/r/ABT-267 ABT-333Ribavirin (RBV)
|
3b
|
M14-423
|
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer
|
Ongoing
|
Pertuzumab / Trastuzumab / Taxane
|
3b
|
MO28047
|
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah)
|
|
The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias
|
Ongoing
|
Deferiprone Deferoxamine
|
3b
|
LA38-0411
|
Aseer Central Hospital, King Abdulaziz University Hospital (Jeddah), King Khalid University Hospital (Riyadh)
|
|
Risk assesment and mangement of Vte in women at risk of thromboEmbolism during pregnancy and puerperium
|
Ongoing
|
N/A
|
4
|
OBS14159
|
King Abdulaziz University Hospital (Jeddah)
|
|
A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SafeHer Study]
|
Ongoing
|
trastuzumab
|
3
|
MO28048
|
King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh)
|
